RBC Capital has reiterated its Outperform rating on shares of Nurix Therapeutics, a clinical-stage biopharmaceutical company focused on targeted protein degradation. The reaffirmation comes as analysts continue to monitor the firm's progress with its lead drug candidates, which aim to treat certain cancers and inflammatory diseases.
Nurix, listed on the Nasdaq, is not directly part of the FTSE 100 or 250, but its shares are held by some UK-based investment trusts and pension funds that allocate to US healthcare equities. The Outperform rating suggests that RBC Capital believes the stock will outperform the broader market or its sector peers over the next 12 to 18 months.
The broader biotech sector has seen renewed interest in recent weeks, driven by dealmaking and positive trial data from several mid-cap developers. UK investors with exposure to global healthcare funds may benefit indirectly from positive sentiment around firms like Nurix, although direct retail holdings are limited.
Analysts at RBC Capital have not provided a specific price target in the reiteration, but the rating implies a degree of upside from current levels. The firm's research note highlighted the potential of Nurix's platform technology, which is seen as a differentiator in the competitive drug discovery landscape.
For UK pension holders and investors with diversified portfolios, analyst ratings on US biotech stocks serve as a barometer for risk appetite in the healthcare sector. A sustained Outperform rating can support valuations in the space, though individual stock performance remains subject to clinical trial outcomes and regulatory decisions.
Source: RBC Capital